Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA_1c, in Patients With Type 2 Diabetes.

ABSTRACT:

Objective

To examine the effect of combination therapy with canagliflozin plus liraglutide on HbA_1c, endogenous glucose production (EGP), and body weight versus each therapy alone.

Research design and methods

Forty-five patients with poorly controlled (HbA_1c 7-11%) type 2 diabetes mellitus (T2DM) on metformin with or without sulfonylurea received a 9-h measurement of EGP with [3-³H]glucose infusion, after which they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks. At 16 weeks, the EGP measurement was repeated.

Results

The mean decrease from baseline to 16 weeks in HbA_1c was -1.67 ±

SUBMITTER: Ali AM 

PROVIDER: S-EPMC7411279 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature